B230380D07Rik Inhibitors
Chemical inhibitors of B230380D07Rik operate through various molecular mechanisms to inhibit its activity. Palbociclib, a CDK4/6 inhibitor, arrests the cell cycle at the G1 phase, which can lead to the inhibition of B230380D07Rik if its activity is associated with cell cycle progression. Similarly, Trametinib, by inhibiting MEK, can downregulate the MEK/ERK pathway, potentially inhibiting B230380D07Rik if its function is tied to this pathway that governs cell proliferation, differentiation, and survival. Rapamycin targets the mTOR pathway, which can result in the reduced protein synthesis and cell proliferation, potentially affecting B230380D07Rik activity if it relies on mTOR signaling. Bortezomib hinders the proteasome, preventing protein degradation; if B230380D07Rik is implicated in these pathways, its inhibition can occur.
Further, Sorafenib and Sunitinib, as tyrosine kinase inhibitors, can inhibit B230380D07Rik by targeting the kinases involved in signaling pathways that regulate cell growth and survival. Dasatinib, broad-spectrum in its kinase inhibition, can prevent the phosphorylation and activation of B230380D07Rik if it is regulated by a kinase susceptible to Dasatinib. Erlotinib and Gefitinib, which selectively inhibit EGFR, can inhibit B230380D07Rik if it is a part of the EGFR signaling cascade. Similarly, Lapatinib targets both EGFR and HER2/neu tyrosine kinases, and can inhibit B230380D07Rik if it operates downstream of these kinases. Lastly, Imatinib and Nilotinib, which are selective BCR-ABL tyrosine kinase inhibitors, can inhibit B230380D07Rik if it interacts with or is regulated by the BCR-ABL pathway, playing a role in cell proliferation and survival. Each inhibitor's interaction with B230380D07Rik depends on the protein's specific involvement in these cellular pathways.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib is a CDK4/6 inhibitor. Assuming B230380D07Rik is regulated by the cell cycle, inhibition of CDK4/6 leads to cell cycle arrest at G1, which could inhibit the activity of B230380D07Rik if it is involved in cell cycle progression. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
Trametinib is a MEK inhibitor. By inhibiting MEK, the MEK/ERK pathway is downregulated, which could inhibit B230380D07Rik activity if it is involved in this signaling pathway that regulates cell proliferation, differentiation, and survival. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits the mTOR pathway, leading to reduced protein synthesis and cell proliferation. Inhibition of the mTOR pathway could inhibit B230380D07Rik activity if it relies on mTOR signaling for its function. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor that prevents the degradation of proteins involved in cell cycle regulation. If B230380D07Rik is involved in protein degradation pathways, inhibition of the proteasome could lead to functional inhibition of B230380D07Rik. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a tyrosine kinase inhibitor. It inhibits multiple kinases, potentially leading to inhibition of B230380D07Rik if it is involved in signaling pathways regulated by these kinases, particularly those that control cell growth and survival. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor which could inhibit B230380D07Rik activity if the protein's function is regulated by a kinase that Dasatinib inhibits, leading to reduced phosphorylation and activation of the protein. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib selectively inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase, which could inhibit B230380D07Rik if it is involved in the EGFR signaling pathway, leading to inhibition of downstream signaling processes that B230380D07Rik is part of. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib is a BCR-ABL tyrosine kinase inhibitor, and if B230380D07Rik is involved in the BCR-ABL signaling pathway, its inhibition would result in the functional inhibition of B230380D07Rik by preventing its activation or the signaling processes it is involved in. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Sunitinib is a receptor tyrosine kinase inhibitor, which could inhibit B230380D07Rik if it functions downstream of or is regulated by receptor tyrosine kinases that Sunitinib targets, leading to reduced activation and function of B230380D07Rik in processes like angiogenesis or cell survival. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $205.00 $405.00 | 9 | |
Nilotinib is a selective BCR-ABL tyrosine kinase inhibitor. Inhibiting BCR-ABL could lead to the functional inhibition of B230380D07Rik if it is regulated by or interacts with the BCR-ABL pathway, which is involved in cell proliferation and survival. | ||||||